CRVS vs. TPST, KRON, GBIO, VHAQ, TRVI, ANVS, KPTI, RLYB, PYXS, and AFMD
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Tempest Therapeutics (TPST), Kronos Bio (KRON), Generation Bio (GBIO), Viveon Health Acquisition (VHAQ), Trevi Therapeutics (TRVI), Annovis Bio (ANVS), Karyopharm Therapeutics (KPTI), Rallybio (RLYB), Pyxis Oncology (PYXS), and Affimed (AFMD). These companies are all part of the "pharmaceutical preparations" industry.
Corvus Pharmaceuticals (NASDAQ:CRVS) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations.
39.8% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.7% of Tempest Therapeutics shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Corvus Pharmaceuticals received 195 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. However, 62.86% of users gave Tempest Therapeutics an outperform vote while only 62.20% of users gave Corvus Pharmaceuticals an outperform vote.
In the previous week, Tempest Therapeutics had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Tempest Therapeutics and 0 mentions for Corvus Pharmaceuticals. Tempest Therapeutics' average media sentiment score of 1.07 beat Corvus Pharmaceuticals' score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the news media.
Corvus Pharmaceuticals presently has a consensus price target of $6.63, indicating a potential upside of 303.96%. Tempest Therapeutics has a consensus price target of $22.33, indicating a potential upside of 615.81%. Given Tempest Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tempest Therapeutics is more favorable than Corvus Pharmaceuticals.
Corvus Pharmaceuticals' return on equity of -60.76% beat Tempest Therapeutics' return on equity.
Corvus Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.3, indicating that its stock price is 230% less volatile than the S&P 500.
Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Corvus Pharmaceuticals and Tempest Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
